Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Seattle Genetics evaluates SGN-15/Taxotere combination in phase II

Nov. 7, 2000

KS Biomedix and York Medical sign high-affinity antibody deal

Nov. 7, 2000

KRN-7000 as an adjunct to surgical removal of tumors

Nov. 3, 2000

Xoma initiates phase I trial with ING-1 monoclonal antibody

Nov. 2, 2000

Melacine as adjuvant therapy in melanoma: phase III data reported at SBT meeting

Oct. 30, 2000

Immunotherapy with beta-alethine useful in minimal residual disease

Oct. 30, 2000

Therion and Aventis expand cancer vaccine alliance

Oct. 27, 2000

SRL-172 has positive effects on response rate, survival and quality of life in NSCLC

Oct. 24, 2000

TroVax colorectal cancer vaccine approved for phase I/II

Oct. 23, 2000

Oncophage enters phase II sarcoma study; trial marks drug's seventh cancer indication

Oct. 23, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...